Stockreport

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Inozyme Pharma, Inc.  (INZY) 
PDF – Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end [Read more]